| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $22,200 | 1 | 100 |
| REYNO LEONARD | Chief Medical Officer | 0 | $0 | 1 | $22,200 | $-22,200 |
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various …
Over the last 12 months, insiders at C4 Therapeutics, Inc. have bought $0 and sold $22,200 worth of C4 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at C4 Therapeutics, Inc. have bought $57,868 and sold $360,677 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,667 shares for transaction amount of $31,735 was made by Koppikar Utpal (director) on 2023‑02‑08.
| 2026-01-16 | Sale | REYNO LEONARD | Chief Medical Officer | 10,000 0.0139% | $2.22 | $22,200 | +42.15% | |
| 2025-02-18 | Sale | Boyle Scott N | Chief Business Officer | 669 0.0009% | $3.15 | $2,107 | -27.27% | |
| 2025-02-14 | Sale | Boyle Scott N | Chief Business Officer | 490 0.0007% | $3.15 | $1,544 | -31.45% | |
| 2023-02-08 | Koppikar Utpal | director | 5,667 0.0109% | $5.60 | $31,735 | -44.28% | ||
| 2022-04-12 | Hirsch Andrew | President & CEO | 10,000 0.0196% | $8.40 | $84,000 | -7.59% | ||
| 2022-01-04 | Sale | Crystal Adam | Chief Medical Officer | 30,000 0.0617% | $31.66 | $949,935 | -69.95% | |
| 2021-12-17 | Sale | Salter Malcolm | director | 1,510 0.0032% | $30.25 | $45,678 | -69.12% | |
| 2021-11-19 | Sale | Salter Malcolm | director | 1,510 0.0034% | $40.11 | $60,566 | -73.29% | |
| 2021-10-15 | Sale | Salter Malcolm | director | 1,510 0.0034% | $44.94 | $67,859 | -72.36% | |
| 2021-10-01 | Sale | Crystal Adam | Chief Medical Officer | 30,000 0.0644% | $45.43 | $1.36M | -54.31% | |
| 2021-09-27 | Sale | Prokupets Elena | director | 3,700 0.0076% | $50.04 | $185,146 | -56.99% | |
| 2021-09-24 | Sale | Prokupets Elena | director | 6,030 0.0127% | $50.10 | $302,130 | -56.18% | |
| 2021-09-23 | Sale | Prokupets Elena | director | 38,360 0.079% | $50.41 | $1.93M | -56.89% | |
| 2021-09-22 | Sale | Prokupets Elena | director | 21,096 0.0435% | $50.10 | $1.06M | -55.96% | |
| 2021-09-21 | Sale | Prokupets Elena | director | 20,642 0.0426% | $50.14 | $1.03M | -55.74% | |
| 2021-09-17 | Sale | Prokupets Elena | director | 21,680 0.0448% | $50.05 | $1.08M | -55.30% | |
| 2021-09-17 | Sale | Salter Malcolm | director | 1,510 0.0031% | $49.89 | $75,334 | -55.30% | |
| 2021-09-16 | Sale | Prokupets Elena | director | 52,998 0.1074% | $48.65 | $2.58M | -54.79% | |
| 2021-09-15 | Sale | Prokupets Elena | director | 108,386 0.2237% | $48.82 | $5.29M | -53.81% | |
| 2021-09-14 | Sale | Prokupets Elena | director | 1,968 0.0041% | $50.02 | $98,434 | -54.13% |
| Salter Malcolm | director | 10952 0.0089% | $35,155.92 | 1 | 8 | +39.65% |
| Hirsch Andrew | President & CEO | 10000 0.0081% | $32,100.00 | 1 | 0 | <0.0001% |
| Koppikar Utpal | director | 5667 0.0046% | $18,191.07 | 1 | 0 | <0.0001% |
| MCKEE WILLIAM | Chief Financial Officer | 5263 0.0043% | $16,894.23 | 1 | 0 | +39.65% |
| COHEN MARC A | 5030 0.0041% | $16,146.30 | 1 | 0 | +39.65% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$50,191,994 | 27 | 106.80% | $466.61M |
| Increased Positions | 67 | +72.83% | 38M | +72.82% |
| Decreased Positions | 39 | -42.39% | 11M | -20.91% |
| New Positions | 24 | New | 19M | New |
| Sold Out Positions | 16 | Sold Out | 2M | Sold Out |
| Total Postitions | 120 | +30.43% | 80M | +51.92% |
| Lynx1 Capital Management Lp | $13,699.00 | 7.32% | 7.1M | 0 | 0% | 2025-09-30 |
| Soleus Capital Management, L.P. | $13,614.00 | 7.27% | 7.05M | +75,000 | +1.07% | 2025-09-30 |
| Orbimed Advisors Llc | $10,104.00 | 5.4% | 5.24M | -2M | -23.35% | 2025-09-30 |
| Morgan Stanley | $9,596.00 | 5.13% | 4.97M | +217,844 | +4.58% | 2025-09-30 |
| Wasatch Advisors Lp | $9,366.00 | 5% | 4.85M | -3M | -34.64% | 2025-09-30 |
| Vanguard Group Inc | $6,160.00 | 3.29% | 3.19M | +173,535 | +5.75% | 2025-09-30 |
| Bank Of America Corp /De/ | $3,963.00 | 2.12% | 2.05M | +45,158 | +2.25% | 2025-09-30 |
| Millennium Management Llc | $3,733.00 | 1.99% | 1.93M | +832,883 | +75.62% | 2025-09-30 |
| Silverarc Capital Management, Llc | $3,662.00 | 1.96% | 1.9M | +2M | New | 2025-09-30 |
| Blackrock, Inc. | $3,080.00 | 1.65% | 1.6M | -232,975 | -12.74% | 2025-09-30 |